Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

5 Feb 2016 07:00

RNS Number : 1592O
IXICO plc
05 February 2016
 

5 February 2016

IXICO plc Director's dealings

 

5 February 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 4 February 2016 that, on the same day, Professor Derek Hill, Chief Executive of the Company, purchased 10,000 Ordinary Shares of 1p each in IXICO at a price of 33.68p pence per Ordinary Share. As a consequence of this share purchase, Professor Derek Hill is beneficially interested in 487,169 Ordinary Shares representing 1.84% of the Company's issued share capital.

 

Enquiries:

 

IXICO plc

+44 20 3763 7499

Derek Hill, CEO

Susan Lowther, CFO

Peel Hunt LLP (Nominated Adviser and Broker)

+44 20 7418 8900

James Steel / Oliver Jackson

Daniel Stewart & Company (Joint Broker)

+44 207 776 6550

Martin Lampshire / David Coffman

FTI Consulting Limited (Investor Relations)

+44 20 3727 1000

Simon Conway / Mo Noonan / Matthew Moss

 

 

Notes to Editors

 

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

 

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKZLFBQLFLBBL
Date   Source Headline
16th Dec 20247:00 amRNS-RCommercial agreement with PETNET Solutions Inc
10th Dec 20247:00 amRNSContract Win
4th Dec 202411:35 amRNSShare Option Award & PDMR Dealings
4th Dec 20247:00 amRNSFinancial Results for year ended 30 September 2024
25th Nov 20247:00 amRNSNotice of Results and Investor Presentation
31st Oct 20247:00 amRNSShare Option Awards & PDMR Dealing
30th Oct 20244:50 pmRNSHolding(s) in Company
29th Oct 20244:00 pmRNSHolding(s) in Company
29th Oct 202410:58 amRNSHolding(s) in Company
28th Oct 20244:59 pmRNSHolding(s) in Company
28th Oct 202411:00 amRNSDirector/PDMR Shareholdings
25th Oct 202412:55 pmRNSResult of GM, Issue of Equity & TVR
22nd Oct 20243:00 pmRNSCorrection of clerical error
17th Oct 20247:00 amRNSHolding(s) in Company
16th Oct 20247:00 amRNSDirector/PDMR Shareholding
15th Oct 20247:00 amRNSResult of Retail Offer
10th Oct 20241:30 pmRNSExercise of Options & Director/PDMR Purchase
9th Oct 20247:00 amRNSResult of Placing and Subscription
8th Oct 20244:40 pmRNSRetail Offer
8th Oct 20244:35 pmRNSPlacing and Subscription
14th Aug 20247:01 amRNSTrading Update
14th Aug 20247:00 amRNSContract Win
5th Aug 20247:00 amRNSBoard Appointment
29th Jul 20247:00 amRNSFurther progress in HD consortium
20th Jun 20245:45 pmRNSHolding(s) in Company
19th Jun 20247:00 amRNSContract Win
23rd May 20247:00 amRNSContract Win
21st May 20247:00 amRNSHalf-year Report
7th May 20247:00 amRNSNotice of half year results
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.